NYSE$LH
Laboratory Corp Of America Holdings · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Labcorp delivered exceptional results driven by both organic and inorganic growth.
Labcorp announced its Q4 2024 and full year results, demonstrating strong performance. Q4 revenue reached $3.33 billion compared to $3.03 billion in the previous year. The company's diluted EPS for Q4 was $1.70, a significant increase from $(1.95) in the prior year. Adjusted EPS for Q4 was $3.45 compared to $3.30 last year. Free cash flow for Q4 was $665.1 million, up from $412.4 million year-over-year. For full year 2024, revenue was $13.01 billion versus $12.16 billion in 2023, diluted EPS was $8.84 versus $4.33, adjusted EPS was $14.57 versus $13.56, and free cash flow was $1.10 billion versus $748.7 million.
- Q4 revenue increased to $3.33 billion from $3.03 billion year-over-year.
- Q4 diluted EPS was $1.70, a significant improvement from $(1.95) in the previous year.
- Q4 adjusted EPS rose to $3.45 from $3.30 year-over-year.
- Full year 2025 guidance projects revenue between $13.88 billion and $14.05 billion and adjusted EPS between $15.60 and $16.40.
Headline financials
Revenue & EPS history
LabCorp · Revenue · Quarterly
$3.33B
Revenue by segment
LabCorp · $3.06B total across 2 segments · Q3 2023
- Diagnostics Laboratories$2.34B+6.0%76.5%
- Biopharma Laboratory Services$719M-48.8%23.5%
Forward guidance
Labcorp provided its full-year 2025 guidance, anticipating revenue between $13.88 billion and $14.05 billion, and adjusted EPS between $15.60 and $16.40. Free cash flow is projected to be between $1.10 billion and $1.25 billion.
Tailwinds
- Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4%
- Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8%
- Free Cash Flow of $1.10 billion to $1.25 billion; midpoint growth of 7.2%
- Diagnostics Laboratories revenue growth of 6.5% to 7.7%
- Biopharma Laboratory Services revenue growth of 3.0% to 5.0%
Headwinds
- Guidance assumes foreign exchange rates effective as of December 31, 2024.
- Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
- 2025 Guidance includes an impact from foreign currency translation of (0.5%).
- 2025 Guidance includes an impact from foreign currency translation of (0.2%) for Diagnostics Laboratories.
- 2025 Guidance includes an impact from foreign currency translation of (1.4%) for Biopharma Laboratory Services.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.3%
Avg return
Earnings day
-0.6%
Avg return
5 days after
-0.9%
Avg return
30 days after
48%
35 / 73 earnings
Positive
+9.5%
Q2 2024
Best reaction
-10.4%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.0% | +0.0% | +1.3% | |
| Q4 2025 | -2.1% | +0.0% | -6.6% | |
| Q3 2025 | -5.7% | -7.9% | -2.7% | |
| Q2 2025 | -0.5% | +1.2% | +2.0% | |
| Q1 2025 | +4.7% | +7.9% | +7.5% | |
| Q4 2024 | -0.9% | -1.9% | +1.2% | |
| Q3 2024 | +4.0% | +3.7% | +9.0% | |
| Q2 2024 | +9.5% | +4.8% | +6.7% | |
| Q1 2024 | -4.6% | -3.2% | -4.0% | |
| Q4 2023 | -5.0% | -5.5% | -8.3% | |
| Q3 2023 | +0.6% | +1.0% | +7.6% | |
| Q2 2023 | -1.9% | -2.4% | -3.0% | |
| Q1 2023 | -4.6% | -2.5% | -8.2% | |
| Q4 2022 | +3.2% | -0.4% | -14.1% | |
| Q3 2022 | -2.5% | -3.2% | +5.0% | |
| Q2 2022 | +5.1% | +1.2% | -8.1% | |
| Q1 2022 | -5.0% | -3.1% | +1.9% | |
| Q4 2021 | -1.9% | -6.0% | -5.7% | |
| Q3 2021 | +2.3% | +2.0% | +3.1% | |
| Q2 2021 | +4.6% | +6.0% | +6.1% | |
| Q1 2021 | +1.2% | +4.1% | +4.5% | |
| Q4 2020 | +4.0% | +3.1% | +4.1% | |
| Q3 2020 | +1.0% | -1.1% | -2.7% | |
| Q2 2020 | -3.3% | -4.2% | -13.4% | |
| Q1 2020 | -6.5% | -10.4% | -0.4% | |
| Q4 2019 | +4.1% | +1.8% | -19.5% | |
| Q3 2019 | -2.0% | -2.3% | +0.4% | |
| Q2 2019 | -6.5% | -4.2% | -6.9% | |
| Q1 2019 | +3.7% | +6.1% | +5.1% | |
| Q4 2018 | +2.5% | +3.8% | +3.7% | |
| Q3 2018 | -7.1% | -6.2% | -4.1% | |
| Q2 2018 | -5.4% | -6.4% | -5.3% | |
| Q1 2018 | +3.9% | +2.8% | +9.7% | |
| Q4 2017 | +3.9% | +3.0% | +5.9% | |
| Q3 2017 | +1.7% | +2.2% | +0.2% | |
| Q2 2017 | +2.0% | +1.3% | -1.4% | |
| Q1 2017 | -4.1% | -3.1% | -1.9% | |
| Q4 2016 | +2.4% | +2.4% | +5.4% | |
| Q3 2016 | -10.4% | -9.4% | -7.9% | |
| Q2 2016 | +0.4% | +1.2% | -1.4% | |
| Q1 2016 | +4.1% | — | — | |
| Q4 2015 | +2.8% | — | — | |
| Q3 2015 | +7.8% | — | — | |
| Q2 2015 | +3.8% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | +4.9% | — | — | |
| Q3 2014 | +3.5% | — | — | |
| Q2 2014 | -0.5% | — | — | |
| Q1 2014 | -0.7% | — | — | |
| Q4 2013 | +1.1% | — | — | |
| Q3 2013 | -3.2% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.7% | — | — | |
| Q4 2012 | -1.7% | — | — | |
| Q3 2012 | -4.0% | — | — | |
| Q2 2012 | -9.0% | — | — | |
| Q1 2012 | -3.4% | — | — | |
| Q4 2011 | +2.2% | — | — | |
| Q3 2011 | -6.6% | — | — | |
| Q2 2011 | -0.6% | — | — | |
| Q1 2011 | +1.4% | — | — | |
| Q4 2010 | -0.2% | — | — | |
| Q4 2007 | -0.2% | — | — | |
| Q3 2010 | +1.6% | — | — | |
| Q2 2010 | +0.9% | — | — | |
| Q1 2009 | +1.8% | — | — | |
| Q1 2010 | +1.6% | — | — | |
| Q4 2009 | -0.4% | — | — | |
| Q2 2008 | -1.6% | — | — | |
| Q3 2009 | -1.6% | — | — | |
| Q3 2008 | -1.6% | — | — | |
| Q4 2008 | -1.4% | — | — | |
| Q2 2009 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro